Pacouret G, Barnes S J, Hopkins G, Charbonnier B
Cardiologie D Department, Trousseau Hospital, Tours, France.
Thromb Haemost. 1998 Feb;79(2):264-7.
In a single centre pilot study, saruplase (20 mg bolus plus 60 mg infusion over 1 h) was administered to twenty patients with an angiographically documented recent massive pulmonary embolism: Miller index of at least 20 and mean pulmonary artery pressure of at least 20 mmHg. The lytic ability of saruplase to cause normalization of haemodynamic parameters over the first 12 h and reperfusion of pulmonary arteries at 24 h was assessed. A decrease of 25 +/- 10% in total pulmonary resistance was evident at 30 min. Haemodynamic parameters continued to improve with total pulmonary resistance decreasing by 29 +/- 8% and 40 +/- 11% at 1 and 12 h respectively. Relative improvement in Miller index 24 +/- 6 h after saruplase treatment was 38 +/- 9%. Two patients suffered recurrent pulmonary embolism, two severe bleeding events were observed. One patient died following a haemorrhagic stroke.
在一项单中心试点研究中，对20例经血管造影证实近期发生大面积肺栓塞的患者给予沙芦普酶（20 mg静脉推注加60 mg在1小时内输注）：米勒指数至少为20且平均肺动脉压至少为20 mmHg。评估了沙芦普酶在最初12小时内使血流动力学参数正常化以及在24小时时使肺动脉再灌注的溶栓能力。30分钟时总肺阻力明显下降25±10%。血流动力学参数持续改善，总肺阻力在1小时和12小时时分别下降29±8%和40±11%。沙芦普酶治疗后24±6小时米勒指数的相对改善为38±9%。2例患者发生复发性肺栓塞，观察到2例严重出血事件。1例患者因出血性中风死亡。
